CO5700767A2 - Procedimiento de tratamiento de rechazo de transplantes - Google Patents

Procedimiento de tratamiento de rechazo de transplantes

Info

Publication number
CO5700767A2
CO5700767A2 CO06056308A CO06056308A CO5700767A2 CO 5700767 A2 CO5700767 A2 CO 5700767A2 CO 06056308 A CO06056308 A CO 06056308A CO 06056308 A CO06056308 A CO 06056308A CO 5700767 A2 CO5700767 A2 CO 5700767A2
Authority
CO
Colombia
Prior art keywords
transplant rejection
treatment procedure
rejection treatment
procedure
administering
Prior art date
Application number
CO06056308A
Other languages
English (en)
Inventor
Paul Steven Changelian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5700767A2 publication Critical patent/CO5700767A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Un procedimiento para tratar o prevenir el rechazo crónico de transplantes de órganos que comprende administrar un compuesto de fórmula: en la que R1, R2 y R3 son como se han definido anteriormente.
CO06056308A 2003-12-17 2006-06-09 Procedimiento de tratamiento de rechazo de transplantes CO5700767A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53118003P 2003-12-17 2003-12-17

Publications (1)

Publication Number Publication Date
CO5700767A2 true CO5700767A2 (es) 2006-11-30

Family

ID=34710208

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06056308A CO5700767A2 (es) 2003-12-17 2006-06-09 Procedimiento de tratamiento de rechazo de transplantes

Country Status (17)

Country Link
US (1) US20050159433A1 (es)
EP (1) EP1734967A2 (es)
JP (1) JP2007514729A (es)
KR (1) KR20060096153A (es)
CN (1) CN1893952A (es)
AU (1) AU2004305317A1 (es)
BR (1) BRPI0417803A (es)
CA (1) CA2549485A1 (es)
CO (1) CO5700767A2 (es)
IL (1) IL175812A0 (es)
MX (1) MXPA06007002A (es)
NO (1) NO20062292L (es)
RU (1) RU2006120956A (es)
SG (1) SG133602A1 (es)
TW (1) TW200529853A (es)
WO (1) WO2005060972A2 (es)
ZA (1) ZA200604888B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005675A (es) 1999-12-10 2002-09-02 Pfizer Prod Inc Compuestos de pirrolo(2,3-d)pirimidina.
NZ539901A (en) 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
ES2612196T3 (es) 2005-12-13 2017-05-12 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2173752B2 (en) 2007-06-13 2022-07-13 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
KR20120108042A (ko) 2008-03-11 2012-10-04 인사이트 코포레이션 Ｊａｋ 억제제로서의 아제티딘 및 시클로부탄 유도체
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
EP3026052A1 (en) * 2009-04-20 2016-06-01 Auspex Pharmaceuticals, Inc. Preparation of deuterated piperidine inhibitors of janus kinase 3
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI484962B (zh) 2009-05-22 2015-05-21 Incyte Corp 作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈
JP5690823B2 (ja) 2009-07-08 2015-03-25 レオ ファーマ アクティーゼルスカブ Ｊａｋ受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2486041B1 (en) 2009-10-09 2013-08-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
KR102354472B1 (ko) 2010-03-10 2022-01-21 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
CA2823935A1 (en) 2011-01-07 2012-07-12 Leo Pharma A/S Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
US9115133B2 (en) 2011-03-22 2015-08-25 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
JP5876146B2 (ja) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
JP2015529242A (ja) 2012-09-21 2015-10-05 アドヴィヌス セラピューティクス リミテッドＡｄｖｉｎｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 置換された縮合三環式化合物、組成物およびその医薬用途
HUE055894T2 (hu) 2012-11-15 2021-12-28 Incyte Holdings Corp A ruxolitinib nyújtott felszabadulású dózisformái
CN103896826B (zh) * 2012-12-26 2016-08-03 上海朴颐化学科技有限公司 氮保护的(3r,4r)-3-甲氨基-4-甲基哌啶的不对称合成方法、相关中间体及原料制备方法
WO2014102826A1 (en) * 2012-12-28 2014-07-03 Glenmark Pharmaceuticals Limited; The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
PE20151902A1 (es) 2013-03-06 2015-12-26 Incyte Corp Proceso e intermedios para hacer un inhibidor de jak
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN104059016A (zh) * 2014-06-20 2014-09-24 湖南天地恒一制药有限公司 制备托法替布的中间体及所述中间体的制备方法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
IL277538B1 (en) 2018-03-30 2024-05-01 Incyte Corp Use of JAK inhibitors to treat hidradenitis suppurativa
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53782A (en) * 1866-04-10 Improvement in nut-machines
MXPA02005675A (es) * 1999-12-10 2002-09-02 Pfizer Prod Inc Compuestos de pirrolo(2,3-d)pirimidina.
NZ539901A (en) * 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection

Also Published As

Publication number Publication date
WO2005060972A3 (en) 2005-10-20
CN1893952A (zh) 2007-01-10
NO20062292L (no) 2006-06-14
CA2549485A1 (en) 2005-07-07
US20050159433A1 (en) 2005-07-21
JP2007514729A (ja) 2007-06-07
EP1734967A2 (en) 2006-12-27
WO2005060972A2 (en) 2005-07-07
BRPI0417803A (pt) 2007-04-10
ZA200604888B (en) 2007-11-28
TW200529853A (en) 2005-09-16
RU2006120956A (ru) 2008-01-27
SG133602A1 (en) 2007-07-30
AU2004305317A1 (en) 2005-07-07
KR20060096153A (ko) 2006-09-07
IL175812A0 (en) 2008-04-13
MXPA06007002A (es) 2006-08-31

Similar Documents

Publication Publication Date Title
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
BR0316487A (pt) Método todo de tratamento da rejeição de transplantes
EA200802213A1 (ru) Способы лечения заболеваний крови
ECSP055813A (es) Quinolin-, isoquinolin- y quinazolin-oxialquilamidas y su uso como fungicidas
ECSP088503A (es) COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS
BRPI0518406A2 (pt) composiÇÕes tendo uma alta eficÁcia antiviral e antibacteriana
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
NO20052787L (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
ATE433447T1 (de) Pyrimiidinverbindungen
UY29633A1 (es) Derivados de oxindol
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
CR7864A (es) Piridodiacinas como fungicidas de plantas
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
EA200702175A1 (ru) Синергические фунгицидные комбинации биологически активных веществ
PA8632601A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
DK1791428T3 (da) Sammensætning til behandling af såsæd
RU2012157473A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
UY29723A1 (es) Uso de arilanilidas para tratamiento de semillas
GT200500308A (es) Nonadepsipeptidos acilados ii
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung

Legal Events

Date Code Title Description
FC Application refused